Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

ZN-d5 ZN-c3

Other · developed by K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals

Phase 1/2 Most advanced trial (none active)
ZNTL Developer
1 Registered trials

What is ZN-d5 ZN-c3?

ZN-d5 ZN-c3 is an investigational drug studied in Acute Myeloid Leukemia (AML).

At a glance

Also known as
Study Drug
Drug type
Other
Therapy area
Oncology
Developer
K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. (ZNTL)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05682170 Phase 1/2 Acute Myeloid Leukemia (AML) Terminated ZNTL

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Acute Myeloid Leukemia (AML)

More from K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals

Follow ZNTL, the company behind ZN-d5 ZN-c3

See ZNTL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ZNTL catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.